Benefits
GLP-1 secretion: unpublished manufacturer data only
The supplier reports a crossover study in 36 overweight adults in which 300 mg/day produced greater GLP-1 secretion than placebo (reported as roughly 3.5-fold greater area-under-the-curve and 1.7-fold higher Cmax). This study is unpublished: it has no journal, DOI, PubMed record or trial registration, so its design, analysis and results cannot be independently checked. No peer-reviewed human trial of oleoylethanolamide has measured GLP-1 secretion; the OEA-to-GLP-1 pathway rests on cell and animal work. These figures should be read as manufacturer claims rather than as demonstrated evidence.
Akkermansia muciniphila enrichment
In adults with obesity (BMI 30-40 kg/m²), Trpti at 300 mg/day selectively enriched Akkermansia muciniphila, a beneficial gut bacterium linked to gut barrier function, metabolic health, and reduced inflammation. Akkermansia abundance is often lower in people with obesity and metabolic syndrome. Whether increasing it produces any clinical benefit has not been demonstrated in this or any other trial of this ingredient: the reported enrichment is a microbiome sequencing measurement, not a health outcome.
Faecalibacterium prausnitzii enrichment
The same obesity trial documented enrichment of Faecalibacterium prausnitzii, another beneficial gut bacterium associated with anti-inflammatory effects and gut barrier integrity. How a compound that is neither a prebiotic nor a probiotic shifts these species is not established; direct gut signaling by OEA is one proposed explanation, but the trial did not test the mechanism.
Intestinal barrier function improvement
In the 12-week trial, occludin, a tight-junction protein measured in the laboratory, was higher at week 12. This is a surrogate marker of intestinal barrier integrity rather than a measure of how participants felt or functioned, and the broader intestinal-permeability ('leaky gut') framework remains an area of active research rather than settled science. Whether these laboratory changes translate into any difference in digestive symptoms or general health has not been tested.
Immune modulation (IL-2 up, IL-1β down)
Trpti supplementation increased IL-2 (a regulatory cytokine) and decreased IL-1β (a pro-inflammatory cytokine). These are individual cytokine measurements from a single 12-week trial (IL-2 higher at week 6, IL-1β lower). They are surrogate laboratory markers whose clinical meaning is uncertain, and they do not establish that immune function, infection risk or inflammation-related outcomes are changed.
Reduced appetite and modest weight reduction (generic OEA trial)
Human weight and appetite data come from a small randomized trial of generic oleoylethanolamide, not the branded material: Laleh 2018 (PMID 29787831, n=56 adults with obesity) reported reduced appetite and reduced body weight alongside increased PPAR-alpha expression. The published 12-week trial of the branded ingredient did not report body-weight or BMI outcomes, so no weight-loss effect and no BMI subgroup effect can be attributed to it. Results from one small single-center trial need independent replication before they can be considered established.
PPAR-α activation mechanism
OEA's physiological actions stem largely from high-affinity binding to PPAR-α (peroxisome proliferator-activated receptor-alpha), a nuclear receptor that promotes lipolysis, fatty acid oxidation, and satiety. PPAR-α activation in the small intestine is thought to signal satiety to the brain via vagal afferents. This pathway is characterized mainly in animal studies; in humans, appetite and dietary-intake reductions have been reported in two small trials of generic OEA from a single research group (Laleh 2018, PMID 29787831; Payahoo 2019, PMID 31132422).
Mechanism of action
PPAR-α nuclear receptor binding
OEA binds with high affinity to peroxisome proliferator-activated receptor-alpha (PPAR-α) — a nuclear receptor that regulates lipid metabolism, satiety, and energy homeostasis. PPAR-α activation increases fatty acid oxidation in liver and muscle, promotes lipolysis in adipose tissue, and signals satiety to the brain via vagal afferents from the small intestine.
Intestinal L-cell GLP-1 secretion
In cell and animal models, OEA stimulates GLP-1 release from intestinal L-cells rather than binding GLP-1 receptors directly. This pathway is preclinical only: no published human trial of oleoylethanolamide has measured GLP-1, so whether oral OEA meaningfully changes GLP-1 levels in people is unproven. No comparison with prescription medicines is implied or supported.
Vagal afferent satiety signaling
OEA activates vagal afferent neurons in the small intestine that project to the nucleus tractus solitarius (NTS) and hypothalamic satiety centers. This gut-brain signaling pathway is a key driver of post-meal satiety and reduced subsequent food intake — independent of GLP-1 effects.
LipiSperse® bioavailability enhancement
LipiSperse® is a cold-water-dispersible delivery technology by Pharmako Biotechnologies (Australia). It is designed to disperse OEA in water and carry it through the GI tract, addressing OEA's poor native solubility. Note that no published human study has compared the absorption of LipiSperse-delivered OEA against plain OEA, and all four peer-reviewed OEA trials cited on this page used generic oleoylethanolamide rather than this delivery system.
Proposed gut microbiome modulation
OEA's effects on Akkermansia muciniphila and Faecalibacterium prausnitzii enrichment occur without the supplement itself being a prebiotic or probiotic. Mechanism may involve OEA's effects on intestinal mucus production, gut motility, and microenvironmental conditions that favor these beneficial species. A bidirectional relationship, in which gut bacteria in turn influence endogenous OEA production, has been proposed but was not tested in the trials cited here.
Endocannabinoid-like signaling
OEA is an N-acyl ethanolamide structurally related to anandamide and PEA (palmitoylethanolamide). Unlike anandamide, OEA does not activate CB1 or CB2 cannabinoid receptors — it works primarily via PPAR-α and TRPV1. The structural relationship places OEA in a broader family of endogenous bioactive lipids with metabolic and inflammatory regulatory roles.
Clinical trials
Randomized double-blind placebo-controlled trial of Trpti at 300 mg/day (delivering 250 mg OEA) vs placebo for 12 weeks. Published in Gut Microbes Reports 2026;3(1) (doi: 10.1080/29933935.2026.2622259). Authors: Batacan R et al. Outcomes: shotgun metagenomics, microbiome profiling, intestinal barrier biomarkers, inflammatory markers.
57 adults with obesity (BMI 30-40 kg/m²), age 18-65. 12-week intervention.
Selective enrichment of Akkermansia muciniphila and Faecalibacterium prausnitzii — both linked to gut barrier function and metabolic health. Higher occludin (a tight-junction protein) at week 12, and shifts in inflammatory signaling (IL-2 higher at week 6, IL-1β lower). These are surrogate laboratory biomarkers, not clinical outcomes, and their practical significance is not established. Overall microbial diversity remained stable. The published report does not include body-weight or BMI outcomes, so no weight-loss result or BMI subgroup effect can be attributed to this trial. OEA was safe and well-tolerated with no adverse changes in clinical biomarkers.
Randomized double-blind placebo-controlled crossover trial of Trpti at 150 mg and 300 mg doses vs placebo in overweight but otherwise healthy adults. Primary endpoint: GLP-1 secretion measured over 8 hours after standardized breakfast and lunch test meals. Important limitation: this study is unpublished. No journal publication, DOI, PMID or trial registration has been made available, so the protocol, statistics and results cannot be independently verified or peer-reviewed.
36 overweight adults. Crossover protocol with multiple dose arms.
As reported by the manufacturer, 300 mg produced greater GLP-1 secretion than placebo — a rise within 30 minutes and elevations after both breakfast and lunch, described as approximately 3.5-fold greater AUC and 1.7-fold higher Cmax versus placebo. These figures come from an unpublished report and have not been peer-reviewed or independently verified. The report also describes GLP-1 falling below baseline on the 150 mg dose, with only minor increases on placebo. Because none of this has been published or peer-reviewed, it cannot be independently verified, and it does not establish an effective clinical dose. No peer-reviewed human trial of oleoylethanolamide has measured GLP-1 secretion.
Ongoing clinical trial evaluating whether Trpti can reduce plasma imidazole propionate levels (a gut microbiota-derived metabolite linked to insulin resistance) and improve insulin sensitivity in healthy adults. Three-arm parallel design comparing Trpti 150 mg, Trpti 300 mg, and placebo over 28 days. No public registry identifier (ClinicalTrials.gov or ANZCTR) has been provided for this study.
Healthy adults aged 18+ with BMI 18.5-29.9 kg/m². 28-day intervention.
No results. This trial is ongoing and has reported no outcomes, so it provides no evidence for or against any effect. It is listed here only for transparency about work in progress. Its stated target, the imidazole propionate-insulin sensitivity axis, is a research hypothesis rather than an established mechanism for this ingredient.